<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761953</url>
  </required_header>
  <id_info>
    <org_study_id>831334</org_study_id>
    <nct_id>NCT03761953</nct_id>
  </id_info>
  <brief_title>Oritavancin for Staphylococcus Aureus Infections in Opioid Users</brief_title>
  <official_title>A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus Aureus Infections in Patients With Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a pilot single-arm study consisting of 15 participants evaluating the use of
      oritavancin in the final consolidation phase (last two weeks of treatment) of systemic
      infections with Staphylococcus aureus (S. aureus) in opioid users.

      The purpose of this pilot proposal is to collect information for a subsequent large,
      randomized intervention. Primary endpoints will be 1) Safety and tolerability, and 2)
      Duration of hospitalization and rate of recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an early phase, single center, open label pilot study of 15 participants
      designed to evaluate the effects of oritavancin in patients with Opioid Use Disorder and/or
      Intravenous Drug Use and systemic S. aureus infections. In this study systemic infections
      refers to bacteremia or Infectious Endocarditis. Participants who meet inclusion and
      exclusion criteria will receive a single 1200mg infusion of oritavancin to complete 4 weeks
      of antibiotic therapy (including the inpatient phase) for isolated bacteremia and 6 weeks for
      IE. Participants will be evaluated weekly until completion of treatment and then at week 4
      and week 6 after the infusion of oritavancin. Participants will have blood drawn at each
      visit to monitor for toxicity and pharmacokinetics and will be evaluated clinically and by
      culture for the presence of relapse of the infection. At the last visit, participants will
      have an echocardiogram.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This will be a pilot single-arm study consisting of 15 patients evaluating the use of oritavancin in the final consolidation phase (last two weeks of treatment) of systemic infections with Staphylococcus aureus (S. aureus) in opioid users.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of grade 3 or 4 systemic (i.e., not a local reaction) adverse events associated with the administration of oritavancin</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of relapse of infection</measure>
    <time_frame>6 weeks</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>6 weeks</time_frame>
    <description>Duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of systemic S. aureus infections</measure>
    <time_frame>6 weeks</time_frame>
    <description>Relapse of systemic S. aureus infections. Relapse will be defined as an isolation of the same S. aureus strain in subsequent cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of oritavancin: Cmin (μg/ml)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Cmin (μg/ml) at week 1, 2, 4 and 6 after the administration of oritavancin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction when using oritavancin measured using the Patient Satisfaction Questionnaire Short Form (PSQ-18)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Patient satisfaction will be measured using The Patient Satisfaction Questionnaire Short Form (PSQ-18)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Staphylococcus Aureus Bacteremia</condition>
  <condition>Staphylococcus Aureus Endocarditis</condition>
  <arm_group>
    <arm_group_label>Oritavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of 1200mg of oritavancin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oritavancin Injection</intervention_name>
    <description>single 1200mg infusion of IV oritavancin.</description>
    <arm_group_label>Oritavancin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Systemic infection with S. aureus

          -  Afebrile for &gt;48 hours

          -  Negative blood cultures for at least 48 hours

          -  Absolute neutrophil count (ANC) equal or greater 750/mm3

          -  Hemoglobin &gt; 9.0 g/dL

          -  Platelet count equal or &gt; 50,000/mm3

          -  Creatinine &lt; 2.0 x ULN

          -  AST ; ALT, and alkaline phosphatase &lt; 2.0 x ULN

          -  Willing to use a medically accepted method of contraception

        Exclusion Criteria:

          -  Require valve replacement surgery

          -  Have prosthetic material in body (This includes prosthetic heart valves and/or
             prosthetic joints)

          -  Septic emboli to central nervous system or lungs

          -  Breast feeding during entire participation

          -  Pregnant

          -  Polymicrobial infection

          -  Require anticoagulation

          -  Allergy to vancomycin or oritavancin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Tebas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo Tebas, MD</last_name>
    <phone>2679755735</phone>
    <email>pablo.tebas@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica A Meisner, MD</last_name>
    <phone>2675811420</phone>
    <email>jessica.meisner@uphs.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trials Unit. University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104--607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oritavancin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

